!!Hanns Möhler - Curriculum Vitae
\\
__Present Position__
\\ \\
Vice-director, Swiss National Centre of Neuroscience Research\\
University and ETH Zurich
\\ \\
__University studies__
\\
*1959 - 1962	Study of Chemistry, University of Bonn, Germany
*1962 - 1966	Study of Biochemistry, University of Tübingen, Germany
*1968	Ph.D. in Biochemistry, University of Freiburg, Germany
*1978	Habilitation, University of Freiburg, Germany
\\
__Positions in industry__
\\
*1973 - 1988	Research Department, Hoffmann-La Roche, Basle, Switzerland
*1980 - 1986	Group chief, Hoffmann-La Roche, Basle, Switzerland
*1986 - 1988	Vice-director (science), Hoffmann-La Roche, Basle, Switzerland
\\
__Positions in academia__
\\
*1967 - 1968	Department of Biochemistry, Michigan State University, East Lansing, MI, USA
*1968 - 1971	Department of Biochemistry, University of Freiburg, Germany
*1972 - 1973	Senior Research Scientist, Medical Research Council, London, UK
*1977 - 1984	Assistant Professor (Privatdozent), University of Freiburg, Germany
*1984 - 1988	Associate Professor of Biochemistry (Extraordinarius), University of Freiburg, Germany
*since 1988	Full Professor of Pharmacology, University of Zurich, Switzerland 
*Full Professor of Pharmacology, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH) Zurich, Switzerland
*1988 - 2005	Director, Institute of Pharmacology, University of Zurich
*2001 - 2005	Director, Swiss National Centre of Neuroscience, Zurich, NCCR “Neural Plasticity and Repair”
*2003 - 2005 Director, Centre of Competence in Experimental and Clinical Pharma-Sciences, University and University Hospital of Zurich
*since 2004	Fellow, Collegium Helveticum, University and ETH Zurich
*since 2005	Vice-director, Swiss National Centre of Neuroscience Research
*NCCR "Neural Plasticity and Repair", University and ETH Zurich
\\
__Honorary Lectures__
\\
*2008	Plenary Neuroscience Lecture, Hong Kong University of Science and Technology, Hong Kong
*2007	Wyeth Lecture, University of Philadelphia, Philadelphia, USA
*2006	Plenary Lecture, University of Auckland, Medical School, Auckland, New Zealand
*2006	Plenary Lecture, American College of Neuropsychopharmacology, Florida, USA
*2005	Plenary Lecture, International Society of Neurochemistry, Biannual Congress, Innsbruck, Austria
*2004	Elected Fellow, Collegium Helveticum, Zurich, Switzerland
*2004	Gary Price Memorial Lecture, British Pharmacological Society Meeting, University of Newcastle, UK
*2003	Honorary Lecture on the occasion of the Kraepelin Award, Max-Planck-Institute of Psychiatry, Munich, Germany
*2002	Biology Lecture, ETH Zurich, Switzerland
*2002	Neuroscience Award Lecture, European College of Neuropsychopharmacology (ECNP), Barcelona, Spain
*2001	Neuroscience Award, European College of Neuropsychopharmacology
*2001	Plenary Lecture, International Conference on Radiopharmacy, Interlaken, Switzerland
*2001	Biology Lecture, Kansas University, Kansas City, USA
*1999	Plenary Guest Lecture, World Federation of Societies of Biological Psychiatry, Florence, Italy
*1998	Plenary Guest Lecture, British Association for Psychopharmacology, Cambridge, UK
*1998	Department Lecture, University of California Medical School, Los Angeles, USA
*1997	Plenary Lecture, Symposium National Research Program, Bern, Switzerland
*1997	Plenary Lecture, International Symposium, Membrane Receptors, Signal Transduction and Drug Action, Sapporo, Japan
*1996	Plenary Lecture, Methodology in Receptor Research, Meiringen, Switzerland
*1996	Plenary Lecture, Swiss Society of Biological Psychiatry, Berne, Switzerland
*1995	Paul Turner Memorial Lecture, British Pharmacological Society, Brighton, UK
*1995	Biological Science Lecture, Kansas University, Kansas City, USA
*1995	Boehringer Lecture, University of Mainz, Germany
*1987	Plenary Lecture, International Congress of Pharmacology, Sydney, Australia
\\
__Awards__
\\
*2003	Golden Kraepelin Medal, Max-Planck-Society, Munich, Germany
*2002	Théodore-Ott-Prize of the Swiss Academy of Medical Sciences, Switzerland
*2001	Wachter Prize for Medical Research, University of Innsbruck, Austria
*2001	Neuroscience Award, European College of Neuropsychopharmacology
*2000	Prize of the Foundation Forum Engelberg, Switzerland
\\
__Citation ranking__
\\ \\
Ranked among the ISI Highly Cited Researchers, which comprises the 250 most cited scientists in the entire Neurosciences over the last 25 years. 
\\ \\
His work has been published in top line journals such as Science, Nature, Nature Neuroscience and PNAS.
\\ \\
__Member of academies__
\\
*European Academy of Sciences (Academia Europaea), elected member since 1991
*Swiss Academy of Medical Sciences, Member of the Board (1996-2008)
\\	
__Member of national research boards__
\\
*Swiss Foundation for Excellence and Talent in Biomedical Research (since 2008)
*Roche Research Foundation, Basle (1993-2008)
*Research Commission, ETH Zürich (1996-2000)
*Saurer Foundation, Zürich (since 1993)
\\	
__Member of international research review committees__
\\
*German Science Foundation 
*Austrian Science Foundation 
*Anna Monika Foundation, Dortmund, Germany 
*School of Pharmacy, University of London, UK 
*Research Institute of Molecular Pharmacology (FMP), Berlin, Germany 
*RIKEN Brain Science Institute, Wako-shi, Japan 
*Max-Planck-Society, Katz Minerva Center, Jerusalem, Israel
\\
__Member of Prize Committees__
\\
*Dargut and Milena Kemali Foundation, Naples, Italy (since 2004)
*Heinrich Wieland Prize Committee, Munich, Germany (since 2003)
\\	
__Member of editorial boards__
\\
*Channels (Editorial board since 2007)
*Biochemical Pharmacology (Editorial board since 2004)
*Neurodegenerative Disorders (Editorial board since 2003)
*Current Opinion in Pharmacology (Editorial board 2000-2004)
*Journal of Pharmacology and Experimental Therapeutics (Associate Editor since 1998)
*Archives of Pharmacology (Editorial board 1991 - 2002)
*European Journal of Pharmacology (Editorial board since 1991)
*Molecular Neuropharmacology (1990 - 1994)
\\
__Member of professional societies__
\\ 
*American College of Neuropsychopharmacology (ACNP, elected 2008)
*Society for Neuroscience, USA
*New York Academy of Sciences, USA
*European Neuroscience Association
*Society of Physiological Chemistry, Germany
*Pharmacological Societies, Germany and Switzerland
*European College of Neuropsychopharmacology (ECNP)
\\ 	
__Recent activities in industry__
\\
*Newron AG, Bresso (I), Board of Directors (since 2008)
*Evotec AG, Hamburg (D), Scientific advisory board (since 2004)
*HBM Bioventures, Zug (CH), Scientific advisory board (2002-2009)	
\\ 
__Research objectives__
\\ \\
Hanns Möhler`s research interest is focused on the Therapeutic Neuroscience of mental and neurological disorders. They include sleep disturbances, anxiety disorders, memory deficits, schizophrenia and pain. The analysis involves all levels of biological organization ranging from genetics, cell biology and morphology to neurophysiology and behavior, in order to identify molecular control elements of emotion and cognitive behavior. His research has become the basis for a new pharmacology of psychiatric and neurological disorders, based on the modulation of selective neuronal circuits characterized by specific GABAA receptor subtypes. These discoveries permit the rational design of novel hypnotics, non-sedative anxiolytics, cognition enhancers for schizophrenia and pain suppressants. Clinical studies in anxiety disorders and schizophrenia validate this approach.

	






%%(font-size: 80%;)
%%(text-align:right)
''Last updated: November 2009''
%%
%%